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AbstrACt
background To compare the clinical efficacy of New 
York Esophageal squamous cell carcinoma-1 (NY- ESO-1) 
vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX 
alone in a randomized, double- blind phase II study in 
participants with fully resected melanoma at high risk of 
recurrence.
Methods Participants with resected stage IIc, IIIb, IIIc 
and IV melanoma expressing NY- ESO-1 were randomized 
to treatment with three doses of NY- ESO-1/ISCOMATRIX 
or ISCOMATRIX adjuvant administered intramuscularly at 
4- week intervals, followed by a further dose at 6 months. 
Primary endpoint was the proportion free of relapse at 18 
months in the intention- to- treat (ITT) population and two 
per- protocol populations. Secondary endpoints included 
relapse- free survival (RFS) and overall survival (OS), safety 
and NY- ESO-1 immunity.
results The ITT population comprised 110 participants, 
with 56 randomized to NY- ESO-1/ISCOMATRIX and 54 to 
ISCOMATRIX alone. No significant toxicities were observed. 
There were no differences between the study arms in 
relapses at 18 months or for median time to relapse; 139 
vs 176 days (p=0.296), or relapse rate, 27 (48.2%) vs 26 
(48.1%) (HR 0.913; 95% CI 0.402 to 2.231), respectively. 
RFS and OS were similar between the study arms. Vaccine 
recipients developed strong positive antibody responses 
to NY- ESO-1 (p≤0.0001) and NY- ESO-1- specific CD4+ 
and CD8+ responses. Biopsies following relapse did not 
demonstrate differences in NY- ESO-1 expression between 
the study populations although an exploratory study 
demonstrated reduced (NY- ESO-1)+/Human Leukocyte 
Antigen (HLA) class I+ double- positive cells in biopsies from 
vaccine recipients performed on relapse in 19 participants.
Conclusions The vaccine was well tolerated, however, 
despite inducing antigen- specific immunity, it did not 
affect survival endpoints. Immune escape through the 
downregulation of NY- ESO-1 and/or HLA class I molecules 
on tumor may have contributed to relapse.
IntroduCtIon
NY- ESO-1 is a cancer testis antigen expressed 
in a variety of tumors, but not in normal tissue, 
with the exception of testis and placenta.1 It is 
expressed in approximately 45% of advanced 
stage melanomas.2 Participants with NY- ESO-
1- positive tumors who develop anti- NY- ESO-1 
antibodies3 4 often show detectable CD8+5 6 
and CD4+ NY- ESO-1- specific T- cell responses.7 
Although little is known about the biological 
function of NY- ESO-1, its pattern of expres-
sion and demonstrable spontaneous immuno-
genicity in cancer participants6 has made it an 
attractive candidate antigen for cancer immu-
notherapy and thus, it has been evaluated 
in numerous clinical trials as a vaccine6 8–20 
and targeted with adoptively transferred T 
lymphocytes.21 22
ISCOMATRIX (CSL Limited, Parkville, 
Victoria, Australia)23 is a saponin- based adju-
vant that can induce both antibody and T- cell 
responses and has been previously used as 
an adjuvant with other vaccines.24 We previ-
ously conducted a phase I placebo- controlled 
2 Cebon JS, et al. J Immunother Cancer 2020;8:e000410. doi:10.1136/jitc-2019-000410
Open access 
clinical trial to evaluate the safety and immunogenicity of 
recombinant NY- ESO-1 protein formulated in ISCOMA-
TRIX adjuvant in participants with melanoma.10 A total 
of 46 evaluable participants with fully resected NY- ESO-
1- positive tumors received three intramuscular injections 
of vaccine at 4 weekly intervals. The vaccine was well 
tolerated and high- titer antibody responses, strong skin 
reactions and circulating CD8 and CD4 T cells specific for 
a broad range of NY- ESO-1 epitopes were reported.10 25 
At a later, separate long- term follow- up evaluation, the 
relapse- free survival (RFS) of the late- stage melanoma 
participants in this trial appeared to be superior for those 
vaccinated with NY- ESO-1/ISCOMATRIX compared 
with those who received placebo or NY- ESO-1 alone.26 
With a median follow- up of 3.9 years, 5/19 (26%) partic-
ipants relapsed in the cohorts which received NY- ESO-1 
protein in combination with the adjuvant, whereas 13/23 
(56%) relapsed from cohorts which did not (ie, cohorts 
receiving either placebo (n=8) or NY- ESO-1 protein 
alone (n=15)). This apparently substantial difference in 
outcome could not be explained by differences in recog-
nized prognostic factors.10 26 In addition, loss of NY- ESO-1 
or HLA class I expression in the tumors of those partici-
pants who did relapse raised the possibility that immune 
selective pressure resulted from effective antigen- specific 
cellular cytotoxicity. As is the case in the current trial, 
some participants had cancers expressing NY- ESO-1 in a 
small minority of cells, raising questions as to mechanisms 
for improved outcomes in such participants. Possibilities 
include specific expression of NY- ESO-1 in cancer stem- 
like cells,27 or ‘epitope spreading’ to take in more widely 
expressed antigens.28
We undertook a phase II randomized, double- blind 
clinical trial to determine the clinical efficacy of NY- ESO-1 
conjugated with the adjuvant ISCOMATRIX or of ISCO-
MATRIX alone in participants with resected AJCC stage 
IIc, IIIb, IIIc or IV melanoma.
Methods
eligibility
Participants with resected, histologically confirmed, 
AJCC stage IIc, IIIb, IIIc or IV melanoma were eligible 
for enrolment in this study (LUD2003-009) if their 
tumors showed any expression of NY- ESO-1 antigen 
by immunohistochemistry. Eligible participants were 
vaccinated when they had fully recovered, and within 6 
months, of surgery for melanoma (allowing a minimum 
of 2 weeks from the time of the most recent surgery to 
study entry). Although previous adjuvant therapy for a 
melanoma was accepted if participants had subsequently 
relapsed and undergone resection of relapsed disease, 
they were not eligible if they had prior immunotherapy 
or systemic therapy for melanoma following their most 
recent relapse and/or resection. Eligible participants 
were required to have normal values for laboratory anal-
yses performed within 2 weeks of study entry. Protocol- 
specified limits allowed hemoglobin >100 g/L, platelets 
>100×109/L, INR ≤2, creatinine <0.2 mmol/L, bilirubin 
<30 mmol/L and Alanine aminotransferase (ALT)/
Aspartate aminotransferase (AST) <1.5 x Upper Limit 
of Normal (ULN). Participants were ineligible if they 
had resected cerebral metastases, primary ocular mela-
noma or other known malignancy in the three previous 
years, except for treated non- melanoma skin cancer and 
cervical carcinoma in situ. Chemotherapy, radiation 
therapy or participation in any other clinical trial of an 
investigational agent was not permitted within 4 weeks of 
the first dose on study.
treatment plan
The trial was a double- blind phase II trial comparing 
NY- ESO-1/ISCOMATRIX to ISCOMATRIX alone. 
Because ISCOMATRIX is reactogenic at injection sites, it 
was selected as the non- vaccine control in order to main-
tain study blinding. Briefly, 110 participants enrolled at 18 
clinical centers in the UK11 and Australia/New Zealand 
(six in Australia, one in New Zealand) were randomized 
centrally at a 1:1 ratio into two treatment groups and 
stratified by disease stage (AJCC stage IIc, IIIb, IIIc or IV).
Registration of eligible participants, along with assign-
ment of treatment group, clinical trial training and moni-
toring were provided by Kendle Australia (Australia/New 
Zealand) and Kendle International (UK) in collaboration 
with the Ludwig Institute for Cancer Research (LICR). 
Versagenics (Morrisville, North Carolina, USA) provided 
the statistical plan and data analyses.
Each participant received NY- ESO-1 100 µg formu-
lated with ISCOMATRIX adjuvant, 120 µg or 120 µg 
ISCOMATRIX adjuvant alone. Recombinant NY- ESO-1 
and ISCOMATRIX were manufactured in accordance 
with applicable current Good Manufacturing Practices 
as previously described10 29 by LICR and CSL Australia 
(Parkville, Victoria, Australia). The first three doses were 
given at 4- week intervals at days 1, 29 and 57, (±3 days 
of scheduled date) and the fourth injection at month 6 
(day 183±3 days). Participants who progressed were with-
drawn from treatment but follow- up continued until the 
end of the study. Dose adjustments or adjustments in the 
interval of dosing were permitted when, in the opinion of 
the Investigator at each site, toxicity of sufficient severity 
attributed to the study agent occurred.
Although the study pharmacists at each site were 
unblinded, all other personnel associated with the 
conduct and oversight of the study, including all partici-
pants, remained blinded to the treatment allocation and 
identity of the study drug administered.
Toxicity was assessed every cycle using the National 
Cancer Institute Common Toxicity Criteria for Adverse 
Events V.3.0 (NCI CTCAE v3.0). Safety and tolerability 
of NY- ESO-1/ISCOMATRIX or ISCOMATRIX alone 
were monitored by adverse event reporting, blood chem-
istry, urinalysis, physical examination and vital signs. No 
interim analysis was conducted.
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Assessment of efficacy and safety
The primary objective of this study was to compare the clin-
ical efficacy of four intramuscular injections of NY- ESO-1/
ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone 
in eligible participants with resected melanoma at high 
risk of relapse. The primary endpoint was relapse rate at 
18 months among the intention- to- treat (ITT) and two 
per- protocol (PP) populations, which consisted of all 
relapses regardless of location. Relapse was defined as the 
appearance of any new lesion, which had to be confirmed 
by CT scan. Disease was assessed according to Response 
Evaluation Criteria in Solid Tumors V.1.0.30
The secondary objectives were to evaluate treatment 
safety, median RFS, overall survival (OS) and NY- ESO-
1- specific immunity for participants in each treatment 
group. After completing all four treatment doses and the 
final assessments at month 18, each participant was to be 
followed off- study until disease progression and death. 
Thus, RFS and OS over the entire period of observation 
(study defined plus off- study follow- up) among ITT and 
both PP populations were secondary endpoints for the 
study. For time to event data, Kaplan- Meier life tables 
were used to estimate survival rates (for RFS and OS) and 
determine the survival plots.
Toxicity was defined by NCI CTCAE V.3.0. When the 
primary endpoint was subsequently found not to have 
been met, a supplementary protocol was activated to 
enable collection and analysis of any available tumor 
tissue at relapse and determine NY- ESO-1 and HLA class 
I expression.
statistical analysis
The study was powered on the basis of the observable 
difference between RFS for the treated and placebo popu-
lations in an earlier phase I trial10 26 and was designed to 
detect a clinically meaningful reduction in event rates, 
corresponding to about a 24% difference in recurrence 
rate at 18 months, and equivalent to detecting an HR of 
0.53, assuming a one- sided type I error of 0.05. Assuming 
that 50% of participants in the control arm (ISCOMA-
TRIX) relapsed by 18 months, 50–55 participants were 
needed in each arm to achieve 80% power to detect a 
difference of 24% or more in the rate of RFS between 
the two arms. The percentage of participants who were 
relapse free at 18 months was calculated using the HR, the 
95% CI and p value. The duration of RFS at 18 months 
was compared using the Mann- Whitney U test and HR 
calculated using the Cox regression proportional hazards 
model.
Exploratory analyses, both univariate and multivar-
iate (Cox regression), were performed to determine the 
importance of certain covariates (including sex, age, time 
since diagnosis, primary lesion thickness, disease stage at 
diagnosis, disease stage at study entry, number of recur-
rences prior to entry, time since resection prior to study 
entry), and to identify predictors of time to recurrence. 
Statistical significance was declared when the p value was 
found to be less than or equal to 0.05.
Immune monitoring assays
Induction of immune responses against NY- ESO-1, 
measured by antibody titer and NY- ESO-1- specific T- cell 
assays, was a secondary endpoint of the study. NY- ESO-
1- specific antibodies were measured by ELISA using a 
validated assay, as previously described.7 10 Blood samples 
were collected at baseline, at days 71 and 197, and then 
at 12 and 18 months (online supplementary figure S1A). 
Sera from each time point were assayed concurrently to 
enable direct comparisons of antibody titer. The cut- off 
for antibody positivity was 1:100. The p values were calcu-
lated from a Cochran- Mantel- Haenszel test adjusting for 
location (UK or Australia/New Zealand).
Peripheral blood mononuclear cells (PBMCs) were 
isolated as previously described.31 Cellular immune 
responses were only evaluated in a subset of participants 
at selected study sites, based on accessibility to central 
immune monitoring laboratories in Melbourne, Oxford 
and Auckland. PBMCs (5–7×106) from each of the time 
points were pulsed with 2 µL of a pool containing all 28 
NY- ESO-1 18- mer peptides at 30 µM for 1 hour at 37°C in 
200 µL RPMI +10% FCS (RF10). A pool of viral peptide 
epitopes derived from inFluenza, Epstein- Barr virus and 
Cytomegalovirus (FEC) that covers the most common 
HLA class I alleles was kindly provided by the European 
Vaccine against AIDS (EVA) Center for AIDS Reagents).32 
A FEC- specific T cell internal control, for T cell expan-
sion efficiency, was assessed in parallel. The expanded 
NY- ESO-1- specific T cells (both CD8+ and CD4+) were then 
assessed by interferon-γ intracellular cytokine staining as 
previously described,10 31 using the same peptide pool as 
well as the individual peptides within the pool (online 
supplementary methods and supplementary figure S1B).
Immunohistochemistry for hLA class I and nY-eso-1
Immunohistochemistry and scoring for NY- ESO-1 and 
HLA-1 was performed as previously described.2 26 33 The 
HC-10 antibody (kindly provided by Brian Tait, Victorian 
Transplantation and Immunogenetics Service, Melbourne, 
Australia) preferentially recognizes beta-2- microglobulin- 
free HLA- A, HLA- B, HLA- C heavy chain and was used at 
0.004 µg/L.
Multiplexed immunofluorescence analyses
For the supplemental study LUD2003-009- S, tissue was 
available for 10 participants who received NY- ESO-1/
ISCOMATRIX and nine who received ISCOMATRIX. 
Eligible participants had histological confirmation of 
relapse established by surgical biopsy. In order to eval-
uate HLA class I and NY- ESO-1 coexpression, samples 
were analyzed according to the previously described 
method34 with some modifications (online supplemen-
tary methods): Mouse antihuman HLA class I (clone 
HC-10)35 36 was used at 1:3000 dilution and mouse anti- 
human NY- ESO-1 (clone E978)37 was used at 0.01 µg/mL. 
Scanning of the entire specimen section was performed 
with the Vectra V.3.0 automated multispectral quantita-
tive imaging system (PerkinElmer, CLS142338) using 
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Table 1 Patient characteristics and tumor antigen 
expression
Ny- ESO-1/
ISCOMATRIX
(n=56)
Iscomatrix
(n=54) P value
Mean age (years) 54.5 53.0 0.261*
Sex, n (%) 0.477†
  Female 37 (66.1) 32 (59.3)
  Male 19 (33.9) 22 (40.7)
Race 1.00‡
  White, n (%) 56 (100) 54 (100)
Eastern Cooperative Oncology Group (ECOG) 
performance status, n (%)
0.044†
  0 51 (91.1) 44 (81.5)
  1 2 (3.6) 8 (14.8)
  2–4 0 (0.0) 0 (0.0)
American Joint Committee on Cancer (AJCC) 
stage at study entry, n (%)
0.617†
  IIC 2 (3.6) 7 (13.0)
  IIIB 25 (44.6) 18 (33.3)
  IIIC 11 (19.6) 12 (22.2)
  IV 18 (32.1) 17 (31.5)
Ulceration, n (%) 0.024†
  No 27 (48.2) 17 (31.5)
  Unknown 20 (35.7) 19 (35.2)
  Yes 9 (16.1) 18 (33.3)
Tumor antigen expression 0.114*
  ≤5% 26 (46.4%) 28 (51.9%)
  6%–25% 5 (8.9%) 10 (18.5%)
  26%–50% 2 (3.6%) 3 (5.6%)
  51%–75% 6 (10.7%) 4 (7.4%)
  >75% 17 (30.4%) 9 (16.7%)
*From an ANOVA test with factors treatment and location (UK or 
Australia/New Zealand).
†From a Cochran- Mantel- Haenszel test adjusting for location (UK 
or Australia/New Zealand).
‡Unable to calculate Cochran- Mantel- Haenszel due to insufficient 
value variations.
ANOVA, analysis of variance.
the following filter and exposure settings: DAPI 20 ms, 
FITC 65 ms, Cy3 35 ms. Analysis was performed on 20 
fields for core biopsy samples or 800 fields for tumor 
sections. Image fields for 20 sections from NY- ESO-1/
ISCOMATRIX participants, and 22 sections from ISCO-
MATRIX alone participants were analyzed and scored 
for HLA class I or NY- ESO-1 single- positive, HLA class 
I/NY- ESO-1 double- positive and HLA class I/NY- ESO-1 
double- negative cells, using inForm Tissue Finder V.2.2.1 
software (PerkinElmer, CLS135783).
resuLts
baseline characteristics
Of 623 participants screened at 18 clinical trial sites in 
Australia, New Zealand and UK for participation in the 
trial, 111 were randomized: 56 to the NY- ESO-1/ISCO-
MATRIX arm and 55 to the ISCOMATRIX arm. One 
participant in the ISCOMATRIX arm did not receive the 
allocated intervention. Although there were minor differ-
ences in baseline characteristics between the treatment 
groups (table 1), these were not thought to be clinically 
significant. Participants in the ISCOMATRIX group were 
more likely to have ulceration of the primary tumor 
(p=0.024).
Of the 623 participants screened, tumor samples for 
242 participants (39%) were positive for NY- ESO-1 expres-
sion. Of the 147 eligible participants, 40% had NY- ESO-1 
in <5% of the tumor cells in the submitted samples, and 
only 29% had >50% of tumor cells expressing NY- ESO-1 
(online supplementary table S1). The study populations 
were not optimally balanced for antigen distribution. In 
the NY- ESO-1/ISCOMATRIX group, 41% had tumors 
expressing NY- ESO-1 in >50% of tumor cells surveyed 
by IHC, whereas in the ISCOMATRIX alone cohort only 
24% had this high level of antigen expression (table 1). 
After complete eligibility checks, 111 participants were 
randomly assigned to the two study arms and 110 received 
one of the study agents (figure 1).
Patient disposition and drug exposure
Of the total 111 eligible participants, 110 were randomly 
assigned and received treatment on protocol (figure 1). 
All 110 participants comprised the ITT population and 
of these, 56 were randomized to the NY- ESO-1/ISCOMA-
TRIX arm and 54 to the ISCOMATRIX arm.
Of the 56 participants randomized to the NY- ESO-1/
ISCOMATRIX arm, 27 (48.2%) were withdrawn from the 
study; 24 because of disease progression, and three others 
because of consent withdrawal, protocol violation and 
unavailability of drug supply. In the ISCOMATRIX arm, 
25 (46.3%) participants were withdrawn from the study; 
24 because of disease progression and one due to inter-
ruption to drug supply. The treatment doses received by 
participants in the NY- ESO-1/ISCOMATRIX and ISCO-
MATRIX cohorts respectively were: dose 1 (day 1): 56 and 
54, dose 2 (day 29): 53 (94.6%) and 53 (98.1%), dose 3 
(day 57): 50 (89.3%) and 48 (88.9%) and dose 4 (day 
183); 37 (66.1%) and 39 (72.2%). Only one participant 
in the NY- ESO-1 arm required a dose reduction (30% of 
full dose) at day 183.
toxicity
The safety analyses were based on all participants who 
received at least one injection of study drug (ITT popu-
lation). The vaccine was associated with more frequent 
injection site reactions (discomfort, erythema, pain, etc) 
and a variety of other somatic responses (chills, fatigue, 
influenza- like illness, lethargy, malaise, fever, etc) than 
ISCOMATRIX alone (table 2). In general, treatment 
was well tolerated with no participant withdrawing from 
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Figure 1 Disposition of participants (CONSORT diagram). 
CONSORT, Consolidated Standards of Reporting Trials.
Table 2 Common treatment- related adverse events 
(incidence ≥5% in either arm)
System organ class/
preferred term
NY- ESO-1/
ISCOMATRIX
participants
(n=56)
n (%)
ISCOMATRIX
participants
(n=54)
n (%)
Blood and lymphatic system disorders
  Lymphadenopathy 4 (7.1) 2 (3.7)
Gastrointestinal disorders
  Nausea 9 (16.1) 7 (13.0)
General disorders and administration site conditions
  Chest pain 3 (5.4) 1 (1.9)
  Chills 6 (10.7) 1 (1.9)
  Fatigue 13 (23.2) 16 (29.6)
  Influenza like illness 26 (46.4) 9 (16.7)
  Injection site discomfort 5 (8.9) 1 (1.9)
  Injection site erythema 9 (16.1) 1 (1.9)
  Injection site pain 28 (50.0) 17 (31.5)
  Injection site reaction 16 (28.6) 11 (20.4)
  Lethargy 5 (8.9) 3 (5.6)
  Malaise 3 (5.4) 0 (0.0)
  Fever 6 (10.7) 2 (3.7)
Musculoskeletal and connective tissue disorders
  Arthralgia 8 (14.3) 6 (11.1)
  Back pain 6 (10.7) 5 (9.3)
  Musculoskeletal pain 3 (5.4) 3 (5.6)
  Pain in extremity 9 (16.1) 6 (11.1)
Nervous system disorders
  Headache 18 (32.1) 13 (24.1)
Respiratory, thoracic and mediastinal disorders
  Cough 11 (19.6) 3 5.6)
  Nasopharyngitis 4 (7.1) 2 (3.7)
  Pharyngolaryngeal pain 3 (5.4) 4 (7.4)
Skin and subcutaneous tissue disorders
  Rash 4 (7.1) 5 (9.3)
Surgical and medical procedures
  Mass excision 6 (10.7) 3 (5.6)
either arm due to toxicity. There were no deaths during 
the 18- month treatment period. The most common toxic-
ities experienced by the majority of participants in each 
cohort were low- grade local injection site pain and fever. 
Forty- four (78.6%) and 37 (68.5%) participants experi-
enced ≥4 adverse events during their participation in the 
study in the NY- ESO-1/ISCOMATRIX and ISCOMATRIX 
arms, respectively. The maximum CTCAE toxicity grade 
reported was 3 in 12 (21.4%) in the NY- ESO-1/ISCOMA-
TRIX recipients versus 15 (27.8%) in the ISCOMATRIX 
arm. Of the reported adverse events, 46 (82.1%) of the 
participants in the NY- ESO-1/ISCOMATRIX arm, and 
28 (51.9%) of those in the ISCOMATRIX arm reported 
adverse events that were probably or definitely related to 
the study drug (table 2).
The number of participants who experienced serious 
adverse events was similar in the two groups: 10 (17.9%) 
vs 12 (22.2%) in the NY- ESO-1/ISCOMATRIX and ISCO-
MATRIX treatment arms, respectively. None were related 
to study drug. The frequency of adverse events leading 
to discontinuation of study drug was higher in the ISCO-
MATRIX arm, 7 (13%), than in the NY- ESO-1/ISCOMA-
TRIX arm, 2 (3.6%).
efficacy
Overall, RFS and OS were not significantly different 
between the NY- ESO-1/ISCOMATRIX and ISCOMA-
TRIX groups at 18 months, during the entire period of 
observation or after long- term follow- up (figure 2A,B). 
The median time to relapse for all participants was 139 
days in the NY- ESO-1/ISCOMATRIX arm and 176 days 
in the ISCOMATRIX arm (p=0.296) at 18 months, and 
142 and 176 days (p=0.398), respectively, over the entire 
period of observation (online supplementary table S2). 
No significant difference in relapse rate was observed 
between the NY- ESO-1/ISCOMATRIX arm and the ISCO-
MATRIX arm, 27 (48.2%) vs 26 (48.1%), respectively (HR 
0.913; 95% CI 0.402 to 2.231) at 18 months, or over the 
entire period of observation: 33 (58.9%) and 29 (53.7%), 
respectively (HR 0.880; 95% CI 0.532 to 1.455). Similarly, 
there was no significant difference in RFS between the 
NY- ESO-1/ISCOMATRIX and ISCOMATRIX arms for 
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Figure 2 Relapse- free survival (RFS) and overall survival 
(OS). Kaplan- Meier curves of the ITT population for: (A) RFS 
over the study defined period, (B) OS over the study period 
and long- term follow- up, (C) OS by immunity over study 
period and long- term follow- up and (D) OS by treatment 
and immunity over study period and long- term follow- up. 
ESO/IMX: NY- ESO-1/ISCOMATRIX. IMx: ISCOMATRIX. ITT, 
intention to treat.
Figure 3 NY- ESO-1- specific antibody responses. Total IgG 
(reciprocal titer) over the duration of the study in participants 
vaccinated with (A) NY- ESO-1/ISCOMATRIX (n=51) or (B) 
ISCOMATRIX alone (n=49). Five participants in each group 
are excluded due to lack of data. *Thick line encompasses 
data for 31 participants who did not have antibody 
responses. Shaded area indicates titers below the limit of 
quantitation (<5000). ‡Participants in whom antibody titers 
increased on days 197 or 365, well after the final dose of 
study drug (day 183).
the AJCC Stage at study entry, that is, non- stage IV and 
stage IV groups (online supplementary table S2).
nY-eso-1 immune responses
As expected, there was no significant (p=0.733) difference 
in NY- ESO-1 antibody titers between the two treatment 
groups at baseline prior to receipt of study drug (figure 3 
and online supplementary table S3). Vaccination induced 
a highly significant (p<0.001) difference in antibodies, 
with 95% of participants in the NY- ESO-1/ISCOMATRIX 
group demonstrating antibody responses by day 71 vs 7% 
in the control group (figure 3 and online supplemen-
tary table S4). This difference remained for the dura-
tion of the 18- month study, although the antibody titer 
decreased over time. Nonetheless, nearly all participants 
in the NY- ESO-1/ISCOMATRIX group had elevated anti-
body titers at the end of the study (figure 3A).
A similar number of participants in each study arm had 
pre- existing anti- NY- ESO-1 antibodies at baseline, 16 of 
51 (31%) in the NY- ESO-1/ISCOMATRIX arm and 13 of 
49 (26%) in the ISCOMATRIX arm (online supplemen-
tary table S3). NY- ESO-1/ISCOMATRIX induced a strong 
antibody response in those participants who had negative 
baseline serology. Of the 31 seronegative participants, 
28 (90%) developed vaccine- induced anti- NY- ESO-1 
antibodies. Antibody titers were boosted in 9 of the 16 
(56%) participants who had pre- existing antibodies. 
Seroconversion was rare in the ISCOMATRIX arm. Three 
of the 13 participants (23%) with pre- existing antibody 
had a boost in antibody levels, and 2 of 32 (6%) sero-
negative participants developed NY- ESO-1 specific anti-
bodies. Thus, 5 out of 49 participants (10%) developed or 
increased NY- ESO-1 specific antibodies despite receiving 
ISCOMATRIX adjuvant alone. These increases often 
occurred well after receiving study drug (days 71, 197 
and 365). NY- ESO-1 is highly immunogenic and sponta-
neous antibodies often accompany NY- ESO-1 expression 
in tumors.1 3 38 Since clinical relapses occurred in three of 
these five participants, these were probably spontaneous 
antibody responses against tumor- derived NY- ESO-1. 
Participants with NY- ESO-1 immunity did not have better 
OS than those without (figure 2C,D).
Cellular immunity
Immune monitoring of CD4+ and CD8+ T- lymphocyte 
responses was performed on a subset of 34 accessible 
participants: 19 NY- ESO-1/ISCOMATRIX vaccine recip-
ients and 15 control ISCOMATRIX recipients. Using a 
systematic screening approach with overlapping peptides 
approach, we have previously detected naturally occurring 
NY- ESO-1- specific CD8+ and/or CD4+ T cell responses 
in many melanoma participants.39 Of the participants 
studied here, 13 had evidence of pre- existing cellular 
immunity against NY- ESO-1, 7 prior to NY- ESO-1/ISCO-
MATRIX vaccine and 6 prior to ISCOMATRIX adjuvant 
control (figure 4, hatched bars). Administration of the 
vaccine either boosted pre- existing responses (5/7, 71%) 
or broadened the T- cell response repertoire to recognize 
additional peptide epitopes (16/19, 84%) (figure 4, solid 
bars). In only three vaccine recipients (063–001, 063–004 
and 063–005) were no responses detected. Examples of 
detailed patient immune monitoring data are shown in 
online supplementary figures S2–S6 and illustrate: (1) a 
vaccine response with antibody, CD4+ and CD8+ T cells 
(online supplementary figure S2), (2) a pre- existing 
antibody and CD8+ and CD4+ T cell response in a vacci-
nated patient who developed new CD4+ T cell specific-
ities (online supplementary figure S3), (3) Induction 
of antibody and CD4+ T cells without an apparent CD8+ 
T response in vaccine recipient (online supplemen-
tary figure S4), (4) induction of multiple CD8+ T cell 
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Figure 4 Pre- existing and vaccine- induced T cell responses against NY- ESO-1. T cell responses for 19 participants who 
received NY- ESO-1/ISCOMATRIX and 15 participants who received ISCOMATRIX only. Responses of interest: 062–003 and 
014–006 are difficult to interpret due to weak FACS patterns; 013–013—pre- existing Antibody (Ab), CD4 response at day 365, 
relapse at day 387, suggestive of a spontaneous response; 014–003—pre- existing Ab and CD8, and a strong but transient 
CD4 response on days 197 and 365 reflects spontaneous immunity; 063–003—pre- existing Ab and CD8, uninterpretable CD4 
response. Antibody titer measured as total IgG: IFNγ, interferon-γ; ND, not determined at baseline; NT, no data for patient; p, 
pre- existing; v, vaccine- induced; -, no pre- existing Ab or no vaccine- induced Ab response.
specificities in vaccine recipient (online supplementary 
figure S5).
Additionally, the kinetics and persistence of NY- ESO-1 
specific CD4/CD8+T cell responses over time were 
measured in 31 other patients and these responses are 
shown in online supplementary figure S7.
In most cases, the vaccine induced CD4+ occurred 
more frequently than CD8+ T cell responses (figure 4), 
although there were exceptions such as patient 063–002 
who had CD8+ but no evident CD4+ T cell responses 
(online supplementary figure S5). One possibility reason 
is that this patient may not have expressed the right MHC 
class II molecules for presentation of NY- ESO-1 peptides 
to CD4+ T cells. There are only 10 class II alleles (1 DP 
and 9 DR) thus far reported to present NY- ESO-1 epitopes 
to CD4+ T cells (http:// archive. cancerimmunity. org/ 
peptidedatabase/ tumorspecific. htm). As our study was 
not intended for detailed immune monitoring, the MHC 
class II alleles for all participants and some MHC class I 
alleles for some participants were not typed.
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Online supplementary figure S6 shows pre- existing 
immunity on the basis of a prior antibody response asso-
ciated with emergence of a CD4+ T cell response that was 
most apparent after 6 months but not at later time points 
(days 365 and 547) in a control participant who received 
ISCOMATRIX adjuvant alone. Apparent responses to 
NY- ESO-1 in such placebo recipients alone warrants 
interpretation. Six of the 15 tested had evidence of pre- 
existing spontaneous immunity (five had detectable anti-
body at baseline). Seven developed responses against new 
epitopes (figure 4). In no case does it seem likely that 
ISCOMATRIX actually induced specific immunity against 
NY- ESO-1. Two (participants 062–003 and 014–006) 
showed weak FACS patterns for CD4 and CD8 cells, but 
CD8 reactivity was already present at baseline so ISCO-
MATRIX cannot have initiated recognition. In another, 
two participants (013–013 and 014–003), CD4 responses 
appeared transiently at a time point that was distantly 
removed from administration of ISCOMATRIX (ie, days 
197 and/or 365). Since both had antibody responses at 
baseline, these may also be examples of spontaneous 
T- lymphocyte responses unrelated to the administration 
of study drug. Similarly, participant 063–003 also had a 
pre- existing antibody and CD8 response. In the absence of 
vaccination, these transient T cell responses likely reflect 
reaction against naturally occurring antigen, and lack of 
clinical relapse in such patients (eg, participant 014–003) 
might imply immune control or ‘equilibrium’.40
Coexpression of hLA class I and nY-eso-1
Since tumors were heterogeneous for NY- ESO-1 expres-
sion, and no clinical benefit was seen despite vaccine- 
induced immunity, we investigated the possibility that 
immune responses may have been selectively eradi-
cating NY- ESO-1+ tumor clones but not those that were 
antigen negative. A supplementary protocol was written 
to retrieve tumor blocks on relapse and analyze these for 
antigen expression. Since CD8+ T cell responses depend 
on HLA class I, tumors were characterized for the pres-
ence of double- positive cells bearing both NY- ESO-1 and 
HLA class I. This analysis was initially unplanned and 
it was limited to a relatively small number of available 
samples. Nonetheless, figure 5 shows that double- positive 
cells could be quantified and that in the presence of 
vaccine- induced responses, the abundance of these cells 
was reduced more than in control subjects (figure 5B). 
This supports the hypothesis that NY- ESO-1/ISCOMA-
TRIX vaccination induced immune selection against cells 
expressing HLA class I- restricted NY- ESO-1 epitopes.
ConCLusIons
This phase II clinical trial was undertaken to examine 
the potential clinical impact of a highly immunogenic 
NY- ESO-1 cancer vaccine in melanoma patients. It was 
prompted by an unexpectedly encouraging survival trend 
observed in an earlier phase I trial.10 26 In that trial, we 
studied NY- ESO-1 protein complexed with ISCOMATRIX 
adjuvant. Despite very small numbers, a difference in the 
rates of relapse between vaccine and placebo recipients 
was seen to be compelling, such that further evaluation 
was warranted.
In the phase II trial reported here, NY- ESO-1/ISCOMA-
TRIX vaccine was compared with ISCOMATRIX adjuvant 
alone. Despite being safe and immunogenic, we were not 
able to confirm any difference in rate of relapse, RFS or 
OS. Kaplan- Meier survival estimates for both arms were 
similar for all time points, and there were no statisti-
cally significant predictors of survival among the clinical 
variables examined for primary or secondary survival 
endpoints.
The vaccine was immunologically active. Detailed 
immune monitoring showed that it effectively induced 
both cellular and antibody responses that were specific 
for NY- ESO-1. After three immunizations, 73% of partic-
ipants developed strong specific NY- ESO-1 antibody 
responses (p<0.0001) that often persisted for 12 months 
or more after the final dose of vaccine (figure 3A). Simi-
larly, in the subset of patients that was monitored for 
cellular immunity, an increase in antigen- specific CD8+ 
and CD4+ lymphocytes indicated that humoral immu-
nity was accompanied by cellular immune responses as 
has been previously described.4 7 25 39 41 42 Although occa-
sional changes in anti- NY- ESO-1 immunity were seen in 
ISCOMATRIX adjuvant- alone recipients, these mostly 
occurred on a background of prior spontaneous NY- ESO-1 
immunity (figure 3B, online supplementary figure S6). 
It is likely that endogenous tumor- associated NY- ESO-1 
contributed to this immunity. This is implied from the 
kinetics of these responses. For instance, in several cases 
immunity was boosted well after the final dose of study 
drug on day 365 (figure 3B). Clinical relapses occurred 
in three of five participants, one 13 months into the study 
and the other two at the end of the 18 months. These are 
indicated in figure 3 (‡). For these, the most likely expla-
nation is that endogenous antigen within tumor stimu-
lated the responses. Additionally, when FACS staining 
patterns are weak and associated with a borderline cell 
population, such as for patient 062–003, artifacts arising 
from the methodology can be difficult to distinguish from 
unequivocal positive responses.
Spontaneous immunity is well documented for 
NY- ESO-1, and NY- ESO-1- seropositive participants treated 
with ipilimumab, the anticytotoxic T lymphocyte antigen 
4 antibody. In one study, such participants had a greater 
likelihood of experiencing clinical benefit 24 weeks 
after ipilimumab treatment than NY- ESO-1- seronegative 
participants.43 Our study arms were balanced for this 
confounding factor; 31% of vaccine and 26% in the 
placebo recipients had antibodies that preceded vaccine 
or arose in the absence of vaccination. To assess any 
impact on clinical outcomes, we related survival to immu-
nity rather than randomization and there was no apparent 
impact (figure 2C,D).
We have previously proposed that loss of NY- ESO-1 
or HLA class I can signify immunoediting following 
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Figure 5 Coexpression of HLA class I and NY- ESO-1. Percentage change (top panels) in the number of double- positive 
Human Leukocyte Antigen (HLA)+/NY- ESO-1+ cells relative to prevaccination, and evidence of pre- existing (P) or vaccine- 
induced (V) anti- NY- ESO-1 immunity in a representative number of participants who received (A) NY- ESO-1/ISCOMATRIX or (B) 
ISCOMATRIX alone. Red: positive response for three of three markers (ie, CD4+, CD8+, Ab+). Yellow: positive response for two 
of three markers. Green: positive response for one of three markers. Blue: negative response for all three markers. Gray: data 
not available for this patient. Bottom panels: representative multiplex immunofluorescence for HLA class I (red) and NY- ESO-1 
(green) prevaccination and post- vaccination in a patient (075–015) who received NY- ESO-1/ISCOMATRIX, and in a patient 
(075–009) who received ISCOMATRIX alone. DP, Double positive HLA class I+/ NY- ESO-1+ cells. M, single HLA class I+ cells. NY, 
single NY- ESO-1+ cells. Cell nuclei are stained with 4′,6- diamidino-2- phenylindole (DAPI), magnification: ×20.
NY- ESO-1 immunity.26 This trial provided the opportu-
nity to test this more formally in vaccinated and placebo 
groups, and in particular, to assess tumor cells for the 
simultaneous expression of NY- ESO-1 antigen and HLA 
class I, thereby characterizing the cells that were poten-
tially targetable. Although the analysis was constrained 
by the small numbers from whom tissue was available 
post- relapse, there was a clear trend showing reduced 
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double- positive cells in vaccine recipients compared with 
controls.
In summary, this vaccine was safe and immunogenic, 
however, no apparent clinical benefit was seen in partic-
ipants with Stage IIc, IIIb, IIIc and IV NY- ESO-1+ mela-
noma. Emergent immunity in the control group indicates 
that spontaneous NY- ESO-1 immunity can evolve and 
exploratory studies of NY- ESO-1 and HLA class I expres-
sion suggest that antigen display can also evolve in the 
face of selective pressure in vivo.
As immunotherapy for the treatment of cancer 
continues to develop with highly effective new agents, the 
question inevitably turns to defining a role for antigen- 
specific approaches such as vaccines, alone or in combi-
nation with immune checkpoint inhibitors. Despite being 
immunogenic, further clinical studies of this vaccine as a 
single agent are not planned. Whether or not combina-
tions with immune checkpoint inhibitors can extend the 
efficacy of either or both will require evaluation in appro-
priately designed trials.
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